RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $273.27 million. The enterprise value is $75.05 million.
| Market Cap | 273.27M |
| Enterprise Value | 75.05M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 41.59 million shares outstanding. The number of shares has increased by 2.18% in one year.
| Current Share Class | 41.59M |
| Shares Outstanding | 41.59M |
| Shares Change (YoY) | +2.18% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 5.55% |
| Owned by Institutions (%) | 89.98% |
| Float | 35.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.14 |
| Forward PS | 1.73 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.07 |
| Quick Ratio | 3.57 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,936.71 |
Financial Efficiency
Return on equity (ROE) is -17.35% and return on invested capital (ROIC) is -87.93%.
| Return on Equity (ROE) | -17.35% |
| Return on Assets (ROA) | -10.41% |
| Return on Invested Capital (ROIC) | -87.93% |
| Return on Capital Employed (ROCE) | -20.24% |
| Weighted Average Cost of Capital (WACC) | 10.09% |
| Revenue Per Employee | $276,751 |
| Profits Per Employee | -$101,842 |
| Employee Count | 461 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 0.92 |
Taxes
In the past 12 months, RxSight has paid $110,000 in taxes.
| Income Tax | 110,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.62% in the last 52 weeks. The beta is 1.13, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | -8.62% |
| 50-Day Moving Average | 5.35 |
| 200-Day Moving Average | 7.79 |
| Relative Strength Index (RSI) | 66.29 |
| Average Volume (20 Days) | 956,234 |
Short Selling Information
The latest short interest is 3.84 million, so 9.24% of the outstanding shares have been sold short.
| Short Interest | 3.84M |
| Short Previous Month | 5.51M |
| Short % of Shares Out | 9.24% |
| Short % of Float | 10.93% |
| Short Ratio (days to cover) | 2.59 |
Income Statement
In the last 12 months, RxSight had revenue of $127.58 million and -$46.95 million in losses. Loss per share was -$1.14.
| Revenue | 127.58M |
| Gross Profit | 98.88M |
| Operating Income | -55.11M |
| Pretax Income | -46.84M |
| Net Income | -46.95M |
| EBITDA | -51.58M |
| EBIT | -55.11M |
| Loss Per Share | -$1.14 |
Balance Sheet
The company has $208.80 million in cash and $10.58 million in debt, with a net cash position of $198.22 million or $4.77 per share.
| Cash & Cash Equivalents | 208.80M |
| Total Debt | 10.58M |
| Net Cash | 198.22M |
| Net Cash Per Share | $4.77 |
| Equity (Book Value) | 263.34M |
| Book Value Per Share | 6.33 |
| Working Capital | 246.95M |
Cash Flow
In the last 12 months, operating cash flow was -$22.73 million and capital expenditures -$4.43 million, giving a free cash flow of -$27.17 million.
| Operating Cash Flow | -22.73M |
| Capital Expenditures | -4.43M |
| Depreciation & Amortization | 3.54M |
| Net Borrowing | -24,000 |
| Free Cash Flow | -27.17M |
| FCF Per Share | -$0.65 |
Margins
Gross margin is 77.50%, with operating and profit margins of -43.20% and -36.80%.
| Gross Margin | 77.50% |
| Operating Margin | -43.20% |
| Pretax Margin | -36.71% |
| Profit Margin | -36.80% |
| EBITDA Margin | -40.43% |
| EBIT Margin | -43.20% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.18% |
| Shareholder Yield | -2.18% |
| Earnings Yield | -17.18% |
| FCF Yield | -9.94% |
Analyst Forecast
The average price target for RxSight is $7.79, which is 18.57% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.79 |
| Price Target Difference | 18.57% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 6.60% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 0.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.24 |
| Piotroski F-Score | 2 |